Home > OJU>
Biography

Prof. Hideyuki Akaza

Department of Strategic investigation on comprehensive cancer network

Research Center for Advanced Science and Technology

The University of Tokyo, Japan

 

Email: akazah@med.rcast.u-tokyo.ac.jp

 

Qualifications

 

1980  M.D. The University of Tokyo, Japan

1973  Faculty of Medicine, the University of Tokyo, Japan

 

Publications (Selected)

  1. Hideyuki Akaza, ShiroHinotsu, MichiyukiUsami, Yoichi Arai, Hiroshi Kanetake, Seiji Naito, Yoshihiko Hirao, Study Group for the Combined Androgen Blockade Therapy of Prostate Cancer. Combined Androgen Blockade WithBicalutamide for Advanced Prostate Cancer: Long-Term Follow-Up of a Phase 3, Double-Blind, Randomized Study for Survival. Cacner 2009; 115:3437-3445.
  2. Matthew R. Cooperberg, ShiroHinotsu, MikioNamiki, Kazuto Ito, Jeanette Broering, Peter R. Carroll, Hideyuki Akaza. Risk Assessment Among Prostate Cancer Patients Receiving Primary Androgen Deprivation Therapy. J ClinOncol 2009;27: 4306-4313
  3. Lamm D, Böhle A, Palou J, Persad R, Brausi M, Colombel M, Akaza H, Buckley R. <author reply>Re: Per-Uno Malmström, Richard J. Sylvester, David E. Crawford, et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesicalmitomycin C versus bacillus Calmette-Guerin for non-muscle-invasive bladder cancer. EurUrol 2009; 56:247-56. Eur Urol.2010; 57: e7-9.
  4. Akaza H. Current Asia Pacific Anticancer Therapy and Research Initiatives and Strategies.Jpn J ClinOncol. 2010; 40(Suppl 1): i1.
  5. Akaza H, Hill D, Roh JK, Hao XS. Proposal on the Establishment of Infrastructure for Providing Cancer Treatment in Asia in the Context of Global Health Asia-Pacific Cancer Conference (12-14 November 2009). Jpn J ClinOncol. 2010; 40: i86-i92.
  6. Naito S, Tsukamoto T, Murai M, Fukino K, Akaza H. Overall survival and good tolerability of long-term use of sorafenib after cytokine treatment: final results of a phase II trial of sorafenib in Japanese patients with metastatic renal cell carcinoma. BJU Int. 2011; 108: 1813-9.
  7. Hinotsu S, Akaza H, Naito S, Ozono S, Sumiyoshi Y, Noguchi S, Yamaguchi A, Nagamori S, Terai A, Nasu Y, Kume H, Tomita Y, Tanaka Y, Samma S, Uemura H, Koga H, Tsushima T. Maintenance therapy with bacillus Calmette-Guérin Connaught strain clearly prolongs recurrence-free survival following transurethral resection of bladder tumour for non-muscle-invasive bladder cancer. BJU Int. 2011; 108: 187-95.
  8. Miyazaki J, Kawai K, Kojima T, Oikawa T, Joraku A, Shimazui T, Nakaya A, Yano I, Nakamura T, Harashima H, Akaza H. The liposome-incorporating cell wall skeleton of Mycobacterium bovis bacillus Calmette-Guéin can directly enhance the susceptibility of cancer cells to lymphokine-activated killer cells through up-regulation of natural-killer group 2, member D ligands. BJU Int. 2011; 108:1520-1526.
  9. Tsukamoto T, Shinohara N, Tsuchiya N, Hamamoto Y, Maruoka M, Fujimoto H, Niwakawa M, Uemura H, Usami M, Terai A, Kanayama HO, Sumiyoshi Y, Eto M, Akaza H. Phase III trial of everolimus in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from RECORD-1. Jpn J ClinOncol. 2011; 41:17-24.
  10. Akaza H, Kanetake H, Tsukamoto T, Miyanaga N, Sakai H, Masumori N, Nakatsu H, Sagiyama K, Sakamoto S, Endo Y, Yamanouchi T; REDUCE Study Group. Efficacy and safety of dutasteride on prostate cancer risk reduction in Asian men: the results from the REDUCE study. Jpn J ClinOncol. 2011; 41: 417-23.
  11. Akaza H, Tsukamoto T, Fujioka T, Tomita Y, Kitamura T, Ozono S, Miki T, Naito S, Zembutsu H, Nakamura Y. Combined immunotherapy with low-dose IL-2 plus IFN-alpha for metastatic renal cell carcinoma: survival benefit for selected patients with lung metastasis and serum sodium level. Jpn J ClinOncol. 2011; 41: 1023-30.
  12. Tsuji H, Moriyama K, Nomoto K, Akaza H. Identification of an Enzyme System for Daidzein-to-Equol Conversion in Slackia sp. Strain NATTS. Appl Environ Microbiol 2012; 78: 1228-36.
  13. Akaza H. Prostate Cancer Chemoprevention by Soy Isoflavones-Role of intestinal bacteria as the "second human genome". Cancer Sci 2012; 103: 969-75.
  14. Miyanaga N, Akaza H, Hinotsu S, Fujioka T, Naito S, Namiki M, Takahashi S, Hirao Y, Horie S, Tsukamoto T, Mori M, Tsuji H. Prostate cancer chemoprevention study: an investigative randomized control study using purified isoflavones in men with rising prostate-specific antigen. Cancer Sci.2012; 103: 125-30.
  15. Hinotsu S, Kawai K, Ozono S, Tsushima T, Tokuda N, Nomata K, Naito S, Akaza H. Randomized controlled study of natural interferon α as adjuvant treatment for stage II or III renal cell carcinoma. Int J ClinOncol. 2012; [Epub ahead of print]
  16. Akaza H, Carroll P, Cooperberg MR, Hinotsu S. Fifth Joint Meeting of J-CaP and CaPSURE: Advancing the Global Understanding of Prostate Cancer and Its Management.2012; 42: 226-36.
  17. Ozono S, Ueda T, Hoshi S, Yamaguchi A, Maeda H, Fukuyama Y, Takeda K, Ohashi Y, Tsukamoto T, Naito S, Akaza H. The Efficacy and Safety of Degarelix, a GnRH Antagonist: A 12-month, Multicentre, Randomized, Maintenance Dose-finding Phase II Study in Japanese Patients with Prostate Cancer. Jpn J ClinOncol 2012; 42: 477-84.